BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8989426)

  • 1. Relationship between antigenicity and immunogenicity of chimeric hepatitis B virus core particles carrying HIV type 1 epitopes.
    Grene E; Mezule G; Borisova G; Pumpens P; Bentwich Z; Arnon R
    AIDS Res Hum Retroviruses; 1997 Jan; 13(1):41-51. PubMed ID: 8989426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles.
    von Brunn A; Brand M; Reichhuber C; Morys-Wortmann C; Deinhardt F; Schödel F
    Vaccine; 1993; 11(8):817-24. PubMed ID: 7689283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyhistidine-tagged hepatitis B core particles as carriers of HIV-1/gp120 epitopes of different HIV-1 subtypes.
    Wizemann H; Weiland F; Pfaff E; von Brunn A
    Biol Chem; 2000 Mar; 381(3):231-43. PubMed ID: 10782994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits.
    Isaguliants MG; Kadoshnikov YP; Kalinina TI; Smirnov VD; Wahren B
    Biochemistry (Mosc); 1998 May; 63(5):551-8. PubMed ID: 9632891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
    Fomsgaard A; Nielsen HV; Bryder K; Nielsen C; Machuca R; Bruun L; Hansen J; Buus S
    Scand J Immunol; 1998 Apr; 47(4):289-95. PubMed ID: 9600309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine.
    Takeda S; Shiosaki K; Kaneda Y; Nakasatomi T; Yoshizaki H; Someya K; Konno Y; Eda Y; Kino Y; Yamamoto N; Honda M
    Clin Immunol; 2004 Jul; 112(1):92-105. PubMed ID: 15207786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of recombinant core particles of hepatitis B virus containing epitopes of human immunodeficiency virus 1 core antigen.
    Ulrich R; Borisova GP; Gren E; Berzin I; Pumpen P; Eckert R; Ose V; Siakkou H; Gren EJ; von Baehr R
    Arch Virol; 1992; 126(1-4):321-8. PubMed ID: 1381912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein.
    Zaghouani H; Anderson SA; Sperber KE; Daian C; Kennedy RC; Mayer L; Bona CA
    Proc Natl Acad Sci U S A; 1995 Jan; 92(2):631-5. PubMed ID: 7831341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of V3-specific cytotoxic T lymphocyte responses by HIV gag particles carrying multiple immunodominant V3 epitopes of gp120.
    Luo L; Li Y; Chang JS; Cho SY; Kim TY; Choi MJ; Cheong HS; Kim HJ; Ahn HJ; Min MK; Chun BH; Jung SM; Woo SG; Park SY; Kang CY
    Virology; 1998 Jan; 240(2):316-25. PubMed ID: 9454705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
    Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P
    J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
    Salmon-Céron D; Excler JL; Finkielsztejn L; Autran B; Gluckman JC; Sicard D; Matthews TJ; Meignier B; Valentin C; El Habib R; Blondeau C; Raux M; Moog C; Tartaglia J; Chong P; Klein M; Milcamps B; Heshmati F; Plotkin S
    AIDS Res Hum Retroviruses; 1999 May; 15(7):633-45. PubMed ID: 10331442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes.
    Abdel-Motal UM; Wang S; Awad A; Lu S; Wigglesworth K; Galili U
    Vaccine; 2010 Feb; 28(7):1758-65. PubMed ID: 20034607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavior of a short preS1 epitope on the surface of hepatitis B core particles.
    Borisova G; Borschukova O; Skrastina D; Dislers A; Ose V; Pumpens P; Grens E
    Biol Chem; 1999 Mar; 380(3):315-24. PubMed ID: 10223334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoreactivity of HCV/HBV epitopes displayed in an epitope-presenting system.
    Chen Y; Xiong X; Liu X; Li J; Wen Y; Chen Y; Dai Q; Cao Z; Yu W
    Mol Immunol; 2006 Feb; 43(5):436-42. PubMed ID: 16337486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced immunogenicity and cross-reactivity of HIV-1 V3-peptide and multiple antigen peptides conjugated to distinct carrier proteins.
    Cruz LJ; Cabrales A; Iglesias E; Aguilar JC; González LJ; Reyes O
    Int Immunopharmacol; 2009 Nov; 9(12):1452-9. PubMed ID: 19747570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
    Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
    J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.